Please read the DISCLAIMER at the bottom of the blog.

Rakesh Jhunjhunwala is considered to be the greatest investor in Indian Market. He is supposed to have made Rs 5000 crores by just investing Rs 5000 in Indian Stock Market. Rakesh Jhunjhunwala guru mantra to be successful in stock market is as enumerated below:

(a) He advises people to become interested in a stock when none is interested in the same stock. As per him BUY RIGHT & HOLD TIGHT for years to come. He has been holding few stocks for last 10 years and he is still minting money from those stocks.

(b) He further advises that one should not follow big investors blindly as their risk profile and long term goals with time frame may be difficult to be followed by retail investor.

(c) Market is supreme and every thing is reflected in the price and thus their is no point in fighting the trend as market is always right.

(d) One should be able to create a balance between the fear and greed.

(e) As per his words one has to learn the stock market trading as none can teach the market as stock market experience is the best teacher.

Thus follow Rakesh Jhunjhunwala advice in stock market, BE PATIENT and grow big like Warren Buffet or this iconic man from Dalaal Street.

If you subscribe to this blog with your email, you will get the post right in your INBOX moment it is posted on this blog. Do remember to activate the subscription in your email. GOOD LUCK.

Friday, November 14, 2008

USFDA observations not to affect supply: Lupin

Drug major Lupin today said supply of products manufactured at its Mandideep facility will not be affected despite the US Food and Drug Administration (USFDA) listing as many as 15 observations to be addressed after inspecting the plant.

"The outcome of this inspection does not affect the supply of products manufactured at this facility (Mandideep) across the world, or the approvability of pending applications with the USFDA," the company said in a filing to the Bombay Stock Exchange.

The USFDA had inspected the manufacturing plant as a part of "routine Good Manufacturing Practice," the company said. An inspection report was issued listing 15 inspectional observations. Lupin addressed and presented its actions to eight of these observations right away, the company said. "A complete report to all the observations will be submitted to the FDA expeditiously," the statement added.

The Mandideep facility was earlier inspected in 2003 and 2006, the firm received nine inspectional observations, which were addressed and found acceptable, and the following inspection in 2006 resulted in no inspectional observations, the company said.

"Lupin continues to manufacture and test all products in accordance with the USFDA requirements," it said. The company's shares were trading at Rs 586, down 3.72 per cent in afternoon trade on the BSE.


No comments:


DISCLAIMER: The author is not a registered stockbroker nor a registered advisor and does not give investment advice. His comments are an expression of opinion only and should not be construed in any manner whatsoever as recommendations to buy or sell a stock, option, future, bond, commodity, index or any other financial instrument at any time. While he believes his statements to be true, they always depend on the reliability of his own credible sources. The author recommends that you consult with a qualified investment advisor, one licensed by appropriate regulatory agencies in your legal jurisdiction, before making any investment decisions, and that you confirm the facts on your own before making important investment commitments.

Website hit counters